Amgen reports fiscal Q2 2026 results: revenue $10.05B, up 10% from a year earlier

Amgen filed a Form 8-K with the SEC on Aug 4, 2026, 4:03 PM ET, reporting an event dated Aug 4, 2026. It covers Item 2.02 (Results of Operations and Financial Condition); Item 9.01 (Financial Statements and Exhibits). The results cover fiscal Q2 2026 (quarter ended Jun 30, 2026); figures below are from the company's XBRL financial data filed with the SEC.

• Revenue: $10.05B (+9.5% from $9.18B a year earlier)
• Operating income: $3.51B (+32.3% from $2.66B a year earlier)
• Net income: $2.38B (+65.9% from $1.43B a year earlier)
• Diluted EPS: $4.37 (+64.9% from $2.65 a year earlier)
• Form 8-K accepted by EDGAR Aug 4, 2026, 4:03 PM ET
• Accession number 0000318154-26-000124

SEC filing 8-K · accession 0000318154-26-000124 · sec.gov ↗